Matthew P. Cheng
A5033873670- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
- Bacterial Identification and Susceptibility Testing
- Antimicrobial Resistance in Staphylococcus
- Antifungal resistance and susceptibility
- Fungal Infections and Studies
- Long-Term Effects of COVID-19
- SARS-CoV-2 detection and testing
- Pneumocystis jirovecii pneumonia detection and treatment
- Tuberculosis Research and Epidemiology
- Sepsis Diagnosis and Treatment
- Cytomegalovirus and herpesvirus research
- Antibiotics Pharmacokinetics and Efficacy
- Infective Endocarditis Diagnosis and Management
- Mycobacterium research and diagnosis
- Streptococcal Infections and Treatments
- Clostridium difficile and Clostridium perfringens research
- Antibiotic Resistance in Bacteria
- COVID-19 Impact on Reproduction
- Pneumonia and Respiratory Infections
- Herpesvirus Infections and Treatments
- Immunodeficiency and Autoimmune Disorders
- COVID-19 and healthcare impacts
- Cancer Genomics and Diagnostics
- COVID-19 and Mental Health
McGill University Health Centre
2016-2025
McGill University
2016-2025
Institute of Infection and Immunity
2019-2025
Yale University
2024-2025
Yale Cancer Center
2025
Brigham and Women's Hospital
2018-2024
Dana-Farber Cancer Institute
2018-2024
Office of Infectious Diseases
2011-2024
University of Toronto
2020-2023
Vancouver General Hospital
2022-2023
BackgroundCoronavirus disease 2019 (Covid-19) occurs after exposure to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). For persons who are exposed, the standard of care is observation and quarantine. Whether hydroxychloroquine can prevent symptomatic infection SARS-CoV-2 unknown.MethodsWe conducted a randomized, double-blind, placebo-controlled trial across United States parts Canada testing as postexposure prophylaxis. We enrolled adults had household or occupational someone...
No effective oral therapy exists for early coronavirus disease 2019 (COVID-19).
Several severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines are being deployed, but the global need greatly exceeds supply, and different formulations might be required for specific populations. Here we report Day 42 interim safety immunogenicity data from an observer-blinded, dose escalation, randomized controlled study of a virus-like particle vaccine candidate produced in plants that displays SARS-CoV-2 spike glycoprotein (CoVLP: NCT04450004 ). The co-primary outcomes...
Background: Administering antimicrobial agents before obtaining blood cultures could potentially decrease time to treatment and improve outcomes, but it is unclear how this strategy affects diagnostic sensitivity. Objective: To determine the sensitivity of obtained shortly after initiation therapy in patients with severe manifestations sepsis. Design: Patient-level, single-group, study. (ClinicalTrials.gov: NCT01867905) Setting: 7 emergency departments North America. Participants: Adults...
The role of remdesivir in the treatment patients hospital with COVID-19 remains ill defined a global context. World Health Organization Solidarity randomized controlled trial (RCT) evaluated across many countries, Canada enrolling using an expanded data collection format Canadian Treatments for (CATCO) trial. We report on findings, additional demographics, characteristics and clinical outcomes, to explore potential differential effects different health care systems.
Invasive Scedosporium spp. and Lomentospora prolificans infections are an emerging threat in immunocompromised occasionally healthy hosts. is intrinsically resistant to most, L. all the antifungal drugs currently approved, raising concerns about appropriate treatment decisions. High mortality rates of up 90% underline need for comprehensive diagnostic workup even more new, effective improve patient outcome. For a analysis, we identified cases severe from literature diagnosed 2000 or later...
High-throughput metagenomic sequencing offers an unbiased approach to identify pathogens in clinical samples. Conventional sequencing, however, does not integrate information about the host, which is often critical distinguish infection from infectious disease, and assess severity of disease. Here, we explore utility high-throughput cell-free DNA (cfDNA) after bisulfite conversion map tissue cell types origin host-derived cfDNA, profile bacterial viral metagenome. We applied this assay 51...
Staphylococcus aureus bloodstream (SAB) infection is a common and severe infectious disease, with 90-day mortality of 15%-30%. Despite this, <3000 people have been randomized into clinical trials treatments for SAB infection. The limited evidence base partly results from infections being difficult to complete at scale using traditional trial methods. Here we provide the rationale framework an adaptive platform applied infections. We detail design features Network Adaptive Platform (SNAP)...
Longer Abstract Background The stabilized prefusion form of the SARS-CoV-2 spike protein is produced by transient expression in Nicotiana benthamiana . trimeric glycoproteins are displayed at surface self-assembling Virus-Like-Particles that mimic shape and size virus. candidate vaccine (CoVLP) administered alone or with AS03 CpG1018 adjuvants was evaluated a Phase 1 trial healthy adults. ( ClinicalTrials.gov number NCT04450004 ) Methods study randomized, partially-blinded, prime-boost 21...
Population-level immune surveillance, which includes monitoring exposure and assessing vaccine-induced immunity, is a crucial component of public health decision-making during pandemic. Serosurveys estimating the prevalence severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in population played key role characterizing SARS-CoV-2 epidemiology early phases Existing serosurveys provide infrastructure to continue surveillance but must be adapted remain relevant vaccine era....
Severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) surrogate neutralization assays that obviate the need for viral culture offer substantial advantages regarding throughput and cost. The cPass SARS-CoV-2 Neutralization Antibody Detection Kit (GenScript) is first such commercially available assay detects antibodies block receptor-binding domain (RBD)/angiotensin-converting enzyme (ACE)-2 interaction. We aimed to evaluate inform its use assess added value compared with...